Research Progress of Targeted Ultrasound Contrast Agent BR55.
10.3881/j.issn.1000-503X.12934
- Author:
Xin-Yue ZHANG
1
;
Ke LÜ
1
;
Jian-Chu LI
1
;
Yu-Xin JIANG
1
;
Meng-Su XIAO
1
Author Information
1. Department of Ultrasound,PUMC Hospital,CAMS and PUMC,Beijing 100730,China.
- Publication Type:Review
- Keywords:
targeted ultrasound contrast agent;
ultrasonic molecular imaging;
vascular endothelial growth factor receptor
- MeSH:
Animals;
Contrast Media;
Humans;
Microbubbles;
Molecular Imaging/methods*;
Neovascularization, Pathologic/diagnostic imaging*;
Ultrasonography/methods*;
Vascular Endothelial Growth Factor Receptor-2/analysis*
- From:
Acta Academiae Medicinae Sinicae
2022;44(1):118-122
- CountryChina
- Language:Chinese
-
Abstract:
BR55 is an ultrasound contrast agent targeting vascular endothelial growth factor receptor 2,which can be used to detect tumor neovascularization and improve the diagnostic accuracy.Overseas researchers have used BR55 for human ultrasound molecular imaging,which showed good safety and tolerance.We reviewed the research progress on BR55 applied in the evaluation of tumor neovascularization from the composition,characteristics,animal experiments,and clinical studies of BR55.
